High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer

Oncology

Volumn 68, Issue 1, 2005, Pages 71-78

  Stemmler, J ^a   Mair, W ^b   Stauch, M ^c   Papke, J ^d   Deutsch, G ^e   Abenhardt, W ^b   Dorn, B ^f   Kentenich, C ^a   Malekmohammadi, M ^a   Jackisch, C ^g   Leinung, S ^h   Brudler, O ⁱ   Vehling Kaiser, U ^j   Stamp, J ^k   Heinemann, V ^a,l  

^a UNIVERSITY OF MUNICH   (Germany)

^b Oncological Practice   (Germany)

^c Oncologic Practice   (Germany)

^d Oncologic Practice   (Germany)

^e Diakonissenkrankenhaus   (Germany)

^f Acad Teach and Community Hospital   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h Oncology Practice   (Germany)

ⁱ Hematology and Oncology Practice   (Germany)

^j Oncological Practice   (Germany)

^k SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

Breast cancer, metastatic; Chemotherapy; Docetaxel

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOCETAXEL; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EDEMA; EFFUSION; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RETENTION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 20944433508     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084823     Document Type: Article

References (20)

1. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-2354.
2. Nabholtz JM, Senn HJ, Bezwoda WR, Melnnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M: Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999;17:1413-1424.
3. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottoson-Lönn S, Bengtsson NO, Ostenadt B, Mjaaland I, Palm-Sjöwall M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-1201.
4. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Frageot P, Assadourian S: Docetaxel vs. 5-fluorouracil plus vinblastine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87:1210-1215.
5. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
6. Stemmler HJ, Gutschow K, Sommer H, Malekmohammadi M, Kentenich C, Forstpointner R, Geuenich S, Bischoff J, Hiddemann W, Heinemann V: Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 2001;12:1393-1398.
7. Aihara T, Kim Y, Takatsuka Y: Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002;13:286-292.
8. Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500-3505.
9. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - A phase II single-center study. J Clin Oncol 1999;17:1127-1131.
10. O'Brien MER, Leonard RC, Barrett-Lee PJ, Eggleton SPH, Bizzari JP: Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 1999;10:205-210.
11. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8:147-159.
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457-481.
13. Cox DR: The Analyses of Binary Data. London, Methuen, 1970.
14. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the clinical screening cooperative group of the EORTC. J Clin Oncol 1995;13:214-222.
15. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollup M, Robles M, Bruno R, Norton L: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14/1:58-65.
16. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996;14:422-428.
17. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra I, Earhart RH, Hortobagyi GN, Burris HR 3rd: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-3368.
18. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the clinical screening group of the EORTC. Br J Cancer 1996;74:650-656.
19. 2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 2001;19:336-342.
20. Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R: Canalicular stenosis secondary to weekly docetaxel: A potentially preventable side effect. Ann Oncol 2002;13:218-221.